The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT04917770 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Sintilimab in combination with Multimodality Radiotherapy

Sponsor

West China Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]